

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>		NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>		RELEASE BY SECURED PARTY	
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
OXFORD FINANCE CORPORATION		04/06/2011	BANKING ASSOCIATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	TITAN PHARMACEUTICALS, INC.		
<b>Street Address:</b>	400 OYSTER POINT BLVD., SUITE 505		
<b>City:</b>	SOUTH SAN FRANCISCO		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94080		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	75146837	SPHERAMINE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(858)638-5016		
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>			
<b>Phone:</b>	8586771416		
<b>Email:</b>	lisa.ortiz@dlapiper.com		
<b>Correspondent Name:</b>	DLA Piper LLP (US)		
<b>Address Line 1:</b>	4365 Executive Drive, Suite 1100		
<b>Address Line 2:</b>	Attn: Lisa A. Ortiz		
<b>Address Line 4:</b>	San Diego, CALIFORNIA 92121		
<b>ATTORNEY DOCKET NUMBER:</b>	368986-000014		
<b>NAME OF SUBMITTER:</b>	TROY ZANDER		
<b>Signature:</b>	/S/ TROY ZANDER		

CH \$40.00 75146837

900188628

**TRADEMARK**  
 REEL: 004516 FRAME: 0468

Date:

04/06/2011

Total Attachments: 3

source=Titan - Release#page1.tif

source=Titan - Release#page2.tif

source=Titan - Release#page3.tif

**REASSIGNMENT AND RELEASE OF SECURITY INTEREST**

This Reassignment and Release of Security Interest is executed as of April 6, 2011 by OXFORD FINANCE CORPORATION ("Assignor") for the benefit of TITAN PHARMACEUTICALS, INC., a Delaware corporation ("Assignee").

RECITALS

A. WHEREAS, Assignee assigned certain interests in the intellectual property described on Exhibit A and Exhibit B (the "IP") to the Assignor under that certain Intellectual Property Security Agreement dated as of December 23, 2009, as amended and restated by that certain Amended and Restated Intellectual Property Security Agreement dated as of September 27, 2010, recorded with the U.S. Patent and Trademark Office; and

B. WHEREAS, the Assignor wishes to release and reassign all interest that the Assignor may have in the IP.

AGREEMENT

NOW, THEREFORE, the Assignor agrees that it releases its security interest in the IP and reassigns to Assignee, without warranty or recourse, all interest of the Assignor in the IP.


ASSIGNOR:

Address of ASSIGNOR:

133 North Fairfax Street  
Alexandria, VA 22314

OXFORD FINANCE CORPORATION

By:

  
\_\_\_\_\_

Title:

Vice President & General Counsel

EXHIBIT A

Patents

<u>Description</u>	<u>Pat./Appl.Number</u>	<u>File Date</u>
1. Use of gallium to treat biofilm-associated infections	11700289	1/30/07
2. Implantable polymeric device for sustained release of buprenorphine	10453377	6/2/03
3. Combination of chemotherapeutic drugs for increasing antitumor activity	10521548	8/22/05
4. Implantable polymeric device for sustained release of dopamine agonist	10815481	3/31/04
5. Implantable polymeric device for sustained release of nalmeferene	10856178	5/27/04
6. Use of gallium to treat inflammatory arthritis	11015172	12/17/04
7. Use of pigmented retinal epithelial cells for creation of an immune privilege site	11363911	2/27/06
8. Methods of treating schizophrenia	11497914	8/1/06
9. Treatment and prevention of adverse liver conditions using gallium	11594582	11/7/06
10. Implantable polymeric device for sustained release of buprenorphine	11801302	5/8/07
11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst	11805608	5/23/07
12. Implantable polymeric device for sustained release of dopamine agonist	12119334	5/12/08
13. Method for gene transfer to the central nervous system	6210664	4/3/01
14. Methods of treating schizophrenia	7115256	10/3/06

EXHIBIT B

Trademarks

<u>Description</u>	<u>Serial/ Registration No.</u>	<u>File Date</u>
SPHERAMINE	75146837	8/8/96